254 related articles for article (PubMed ID: 1685443)
1. An overview of peroxisome proliferator-induced hepatocarcinogenesis.
Rao MS; Reddy JK
Environ Health Perspect; 1991 Jun; 93():205-9. PubMed ID: 1685443
[TBL] [Abstract][Full Text] [Related]
2. Lack of expression of glutathione-S-transferase P, gamma-glutamyl transpeptidase, and alpha-fetoprotein messenger RNAs in liver tumors induced by peroxisome proliferators.
Rao MS; Nemali MR; Usuda N; Scarpelli DG; Makino T; Pitot HC; Reddy JK
Cancer Res; 1988 Sep; 48(17):4919-25. PubMed ID: 2457433
[TBL] [Abstract][Full Text] [Related]
3. Differential induction and regulation of peroxisomal enzymes: predictive value of peroxisome proliferation in identifying certain nonmutagenic carcinogens.
Nemali MR; Reddy MK; Usuda N; Reddy PG; Comeau LD; Rao MS; Reddy JK
Toxicol Appl Pharmacol; 1989 Jan; 97(1):72-87. PubMed ID: 2916237
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of hypolipidemic peroxisome proliferator administration on hepatic hydrogen peroxide metabolism in rats.
Tamura H; Iida T; Watanabe T; Suga T
Carcinogenesis; 1990 Mar; 11(3):445-50. PubMed ID: 2311188
[TBL] [Abstract][Full Text] [Related]
5. Oxidative DNA damage caused by persistent peroxisome proliferation: its role in hepatocarcinogenesis.
Reddy JK; Rao MS
Mutat Res; 1989 Sep; 214(1):63-8. PubMed ID: 2671702
[TBL] [Abstract][Full Text] [Related]
6. Comparison of hepatic peroxisome proliferative effect and its implication for hepatocarcinogenicity of phthalate esters, di(2-ethylhexyl) phthalate, and di(2-ethylhexyl) adipate with a hypolipidemic drug.
Reddy JK; Reddy MK; Usman MI; Lalwani ND; Rao MS
Environ Health Perspect; 1986 Mar; 65():317-27. PubMed ID: 3709457
[TBL] [Abstract][Full Text] [Related]
7. Analysis of peroxisome proliferator-induced preneoplastic and neoplastic lesions of rat liver for placental form of glutathione S-transferase and gamma-glutamyltranspeptidase.
Rao MS; Tatematsu M; Subbarao V; Ito N; Reddy JK
Cancer Res; 1986 Oct; 46(10):5287-90. PubMed ID: 2875789
[TBL] [Abstract][Full Text] [Related]
8. In vitro steady-state levels of hydrogen peroxide after exposure of male F344 rats and female B6C3F1 mice to hepatic peroxisome proliferators.
Tomaszewski KE; Agarwal DK; Melnick RL
Carcinogenesis; 1986 Nov; 7(11):1871-6. PubMed ID: 3769136
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-induced hepatocarcinogenesis: levels of activating and detoxifying enzymes in hepatocellular carcinomas induced by ciprofibrate.
Rao MS; Kokkinakis DM; Subbarao V; Reddy JK
Carcinogenesis; 1987 Jan; 8(1):19-23. PubMed ID: 3100085
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator nafenopin potentiated cytotoxicity and genotoxicity of cyclophosphamide in the liver and bone marrow cells.
Voskoboinik I; Drew R; Ahokas JT
Chem Biol Interact; 1997 Jul; 105(2):81-97. PubMed ID: 9251722
[TBL] [Abstract][Full Text] [Related]
11. Inhibition instead of enhancement of lipid peroxidation by pretreatment with the carcinogenic peroxisome proliferator nafenopin in rat liver exposed to a high single dose of corn oil.
Huber WW; Grasl-Kraupp B; Stekel H; Gschwentner C; Lang H; Schulte-Hermann R
Arch Toxicol; 1997; 71(9):575-81. PubMed ID: 9285040
[TBL] [Abstract][Full Text] [Related]
12. [Proliferation of peroxisomes and the hepatocarcinogenic process].
Palut D
Rocz Panstw Zakl Hig; 1997; 48(1):1-11. PubMed ID: 9273657
[TBL] [Abstract][Full Text] [Related]
13. Effects of the hepatocarcinogen nafenopin, a peroxisome proliferator, on the activities of rat liver glutathione-requiring enzymes and catalase in comparison to the action of phenobarbital.
Furukawa K; Numoto S; Furuya K; Furukawa NT; Williams GM
Cancer Res; 1985 Oct; 45(10):5011-9. PubMed ID: 2862989
[TBL] [Abstract][Full Text] [Related]
14. Hepatocarcinogenesis of peroxisome proliferators.
Rao MS; Reddy JK
Ann N Y Acad Sci; 1996 Dec; 804():573-87. PubMed ID: 8993574
[No Abstract] [Full Text] [Related]
15. The peroxisome proliferator class of non-genotoxic hepatocarcinogens synergize with epidermal growth factor to promote clonal expansion of initiated rat hepatocytes.
James NH; Roberts RA
Carcinogenesis; 1994 Dec; 15(12):2687-94. PubMed ID: 8001222
[TBL] [Abstract][Full Text] [Related]
16. Hepatic oxidative stress and related defenses during treatment of mice with acetylsalicylic acid and other peroxisome proliferators.
Cai Y; Appelkvist EL; DePierre JW
J Biochem Toxicol; 1995 Apr; 10(2):87-94. PubMed ID: 7562957
[TBL] [Abstract][Full Text] [Related]
17. Hepatic peroxisome proliferation in rodents and its significance for humans.
Bentley P; Calder I; Elcombe C; Grasso P; Stringer D; Wiegand HJ
Food Chem Toxicol; 1993 Nov; 31(11):857-907. PubMed ID: 8258416
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferation and resistance to hydrogen peroxide in rat hepatocytes: is development of resistance an adaptation to cytotoxicity?
Garberg P; Stenius U; Nilsson K; Högberg J
Carcinogenesis; 1992 Oct; 13(10):1751-8. PubMed ID: 1423834
[TBL] [Abstract][Full Text] [Related]
19. Potent peroxisome proliferators inhibit beta-oxidation in the isolated perfused rat liver.
Bojes HK; Thurman RG
Toxicol Appl Pharmacol; 1996 Oct; 140(2):322-7. PubMed ID: 8887448
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of mdr2 gene by peroxisome proliferators in the mouse liver.
Miranda S; Vollrath V; Wielandt AM; Loyola G; Bronfman M; Chianale J
J Hepatol; 1997 Jun; 26(6):1331-9. PubMed ID: 9210621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
